Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma

Journal Article · · Henry Ford Hospital Medical Journal; (USA)
OSTI ID:6642292
Recently developed radiopharmaceuticals have been proposed for imaging medullary thyroid carcinoma (MTC) with some having therapeutic potential. This study compares the imaging results obtained with radioiodinated meta-iodo-benzylguanidine (MIBG), {sup 99m}Tc (V) DMSA, and {sup 131}I F(ab')2 anti-carcinoembryonic antigen (anti-CEA) in a group of MTC patients. In 23 patients {sup 131}I MIBG imaging showed a high specificity (no false-positive results) but a less satisfactory sensitivity (50%). In 12 patients {sup 99m}Tc (V) DMSA revealed a better sensitivity (77%) but a lower specificity (three false-positive results). Positive results were obtained in two of three patients studied with {sup 131}I F(ab')2 anti-CEA. These data suggest that the highly sensitive {sup 99m}Tc (V) DMSA should be considered as a first choice procedure followed by the highly specific radioiodinated MIBG to confirm the initial results. Since radioiodinated MIBG imaging may have therapeutic usefulness, {sup 131}I MIBG was evaluated in an integrated treatment protocol in four cases of proven MTC. The preliminary results obtained were encouraging.
OSTI ID:
6642292
Journal Information:
Henry Ford Hospital Medical Journal; (USA), Journal Name: Henry Ford Hospital Medical Journal; (USA) Vol. 37:3-4; ISSN HFHJA; ISSN 0018-0416
Country of Publication:
United States
Language:
English